These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32405233)

  • 1. The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection.
    Rajaram S; Canaday LM; Ochayon DE; Rangel KM; Ali A; Gyurova IE; Krishnamurthy D; Fletcher JS; Reighard SD; Cox A; Weirauch MT; Kottyan LC; Deshmukh H; Zacharias WJ; Borchers MT; Waggoner SN
    Immunity; 2020 Jun; 52(6):887-889. PubMed ID: 32405233
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.
    Silla L
    Br J Haematol; 2020 Sep; 190(6):e322-e323. PubMed ID: 32645204
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.
    Lemoli RM; Parisi S; Curti A
    Exp Hematol; 2017 Jan; 45():10-16. PubMed ID: 27826123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of severe ARDS due to SARS-CoV-2 pneumonia using low-flow extracorporeal CO
    Molina Lobo R; Lobo-Valbuena B; Gordo F
    Crit Care; 2021 Oct; 25(1):362. PubMed ID: 34663415
    [No Abstract]   [Full Text] [Related]  

  • 5. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.
    Bošnjak B; Odak I; Ritter C; Stahl K; Graalmann T; Steinbrück L; Blasczyk R; Falk CS; Schulz TF; Wedemeyer HH; Cornberg M; Ganser A; Förster R; Koenecke C
    Front Immunol; 2021; 12():721738. PubMed ID: 34456929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
    Parisi S; Ruggeri L; Dan E; Rizzi S; Sinigaglia B; Ocadlikova D; Bontadini A; Giudice V; Urbani E; Ciardelli S; Sartor C; Cristiano G; Nanni J; Zannoni L; Chirumbolo G; Arpinati M; Lewis RE; Bonifazi F; Marconi G; Martinelli G; Papayannidis C; Paolini S; Velardi A; Cavo M; Lemoli RM; Curti A
    Front Immunol; 2021; 12():804988. PubMed ID: 35173709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cell dysfunction in patients with COVID-19.
    Bi J
    Cell Mol Immunol; 2022 Feb; 19(2):127-129. PubMed ID: 35022604
    [No Abstract]   [Full Text] [Related]  

  • 8. Prospects of chimeric antigen receptor T-cell and natural killer cell therapies in acute leukemias.
    Khan M; Mansoor AE; Olson AL
    Future Oncol; 2016 Oct; 12(19):2179-82. PubMed ID: 27250512
    [No Abstract]   [Full Text] [Related]  

  • 9. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.
    Michel T; Ollert M; Zimmer J
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells.
    Lee DA
    Immunol Rev; 2019 Jul; 290(1):85-99. PubMed ID: 31355489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials.
    Suen WC; Lee WY; Leung KT; Pan XH; Li G
    Cancer Invest; 2018; 36(8):431-457. PubMed ID: 30325244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?
    Ahmed F; Jo DH; Lee SH
    Front Immunol; 2020; 11():586765. PubMed ID: 33365027
    [No Abstract]   [Full Text] [Related]  

  • 14. NK cells in cancer immunotherapy: three decades of discovery.
    Boyiadzis M; Foon KA; Herberman RB
    Discov Med; 2006 Dec; 6(36):243-8. PubMed ID: 17250791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cells: can they be useful as adoptive immunotherapy for cancer?
    Arai S; Klingemann HG
    Expert Opin Biol Ther; 2005 Feb; 5(2):163-72. PubMed ID: 15757378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells: from bench to cancer therapy.
    Boyiadzis M; Foon KA
    Expert Opin Biol Ther; 2006 Oct; 6(10):967-70. PubMed ID: 16989578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically modified immune cells for cancer immunotherapy.
    Jiang L; Wang W
    Sci China Life Sci; 2018 Oct; 61(10):1277-1279. PubMed ID: 30276708
    [No Abstract]   [Full Text] [Related]  

  • 19. Natural killer cells and tumor control.
    Cooley S; Weisdorf DS
    Curr Opin Hematol; 2010 Nov; 17(6):514-21. PubMed ID: 20827184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.